Summary:
double-blinded randomized study to assess the efficacy and safety of NYX-2925 in subjects with Fibromyalgia
Qualified Participants Must:
Between 18-75 yrs of age
Fibromyalgia diagnosis greater than 1yr
no history of bipolar
no history of schizophrenia
no autoimmune disease
marijuana use allowed
Qualified Participants May Receive:
compensation for time and travel.